Trastuzumab (Herceptin)
Sponsors
Armando Santoro, MD, Nagoya City University, Alliance for Clinical Trials in Oncology, Institut Curie, Peking University Cancer Hospital & Institute
Conditions
Advanced/Metastatic Breast CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Breast CancerBreast Cancer, MetastaticBreast Neoplasm, ExerciseEarly Stage HER2+ Breast CancerHER-2 Positive Breast Cancer
Phase 2
Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients
TerminatedNCT00758134
Start: 2008-07-31End: 2010-12-31Updated: 2013-05-29
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
RecruitingNCT07193394
Start: 2026-01-31End: 2029-06-08Target: 20Updated: 2026-02-23
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Not yet recruitingNCT07527806
Start: 2026-05-01End: 2029-12-31Target: 156Updated: 2026-04-17
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)
Not yet recruitingNCT07565324
Start: 2026-04-30End: 2032-12-31Target: 54Updated: 2026-05-04
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
RecruitingNCT07610720
Start: 2026-06-01End: 2029-11-01Target: 57Updated: 2026-05-28
Phase 3
Unknown Phase
Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment
Active, not recruitingNCT06663787
Start: 2024-04-01End: 2026-12-31Target: 50Updated: 2026-05-13
Oncology Treatment Related Ocular Surface Changes
CompletedNCT07666724
Start: 2021-05-18End: 2026-05-31Updated: 2026-06-24